Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Tips from these results
Recent Share tips:
- Sell Hollywood Bowl Group (BOWL) by Robert Stephens (Telegraph) in The Telegraph - Questor
- Long Term Buy British Land Company (BLND) by Joanne Hart in The Daily Mail
- Buy Moneysupermarket.com Group (MONY) by Lucy Tobin in The Times - Tempus
- Buy AltynGold (ALTN) by Tom Winnifrith in ShareProphets
- Hold Capricorn Energy (CNE) by Edmond Jackson in Interactive Investor
- Buy Wishbone Gold (DI) (WSBN) by Hot Stock Rockets in Five Free Share Tips
- Buy Synthomer (SYNT) by Dr. James Fox in The Motley Fool
- Buy Wetherspoon (J.D.) (JDW) by Christopher Ruane in The Motley Fool
- Buy Anglo Asian Mining (AAZ) by Tom Winnifrith in N50
- Buy Macfarlane Group (MACF) by Tom Winnifrith in N50
- Buy Zytronic (ZYT) by Tom Winnifrith in Hot Stock Rockets
- Buy Essentra (ESNT) by Chris Bailey in ShareProphets
- Buy Headlam Group (HEAD) by Chris Bailey in ShareProphets
- Watch Scottish Mortgage Inv Trust (SMT) by Christopher Ruane in The Motley Fool
- Buy Close Brothers Group (CBG) by Shore Capital
- Buy Oxford Nanopore Technologies (ONT) by Berenberg
- Overweight Centrica (CNA) by JP Morgan
- Overweight Drax Group (DRX) by JP Morgan
- Overweight Pearson (PSON) by JP Morgan
- Overweight Babcock International Group (BAB) by JP Morgan
Oxford Biomedica (OXB)
Health Care Sector
| Latest Bid : – | Latest Ask : – |
| High Today : – | Low Today : – |
| This Years High : – | This Years Low : – |
| Volume : – | MKT Cap : – |
Stock Splits and Consolidations
30/05/2018 – Stock Consolidation 50.000:1.000
Oxford Biomedica Overview
Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.Latest Oxford Biomedica Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| – | RBC Capital | – | 2022-04-22 06:35:00 22/04/2022 | – |
| – | Liberum Capital | – | 2022-04-20 09:51:00 20/04/2022 | – |
| – | RBC Capital | – | 2022-03-24 17:46:00 24/03/2022 | – |
| – | Alan Oscroft | – | 2022-02-02 15:55:00 02/02/2022 | – |
| – | RBC Capital | – | 2022-02-01 06:11:00 01/02/2022 | – |
| Latest Bid : – | Latest Ask : – |
| High Today : – | Low Today : – |
| This Years High : – | This Years Low : – |
| Volume : – | MKT Cap : – |
Oxford Biomedica Overview
Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.Latest Oxford Biomedica Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| – | RBC Capital | – | 2022-04-22 06:35:00 22/04/2022 | – |
| – | Liberum Capital | – | 2022-04-20 09:51:00 20/04/2022 | – |
| – | RBC Capital | – | 2022-03-24 17:46:00 24/03/2022 | – |
| – | Alan Oscroft | – | 2022-02-02 15:55:00 02/02/2022 | – |
| – | RBC Capital | – | 2022-02-01 06:11:00 01/02/2022 | – |
Stock Splits and Consolidations
30/05/2018 – Stock Consolidation 50.000:1.000